Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00904995 · ClinicalTrials.gov registry record · Phase 3
Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 23
- Enrollment target
NCT00904995: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00904995 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00904995, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 23 participants
- Enrollment target
Study Summary
Objectives: To investigate the relationship between the administration of intravenous (IV) and oral voriconazole (vori) and the occurrence of false positive (1,3) beta-d- glucan (BG) relative to the standard assessment criteria used to diagnose invasive fungal infection in patients with hematologic malignancies.
Interventions
- DRUG Voriconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00904995
The ClinicalTrials.gov registry entry for NCT00904995 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Voriconazole is the first listed.
NCT00904995 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00904995 about?
NCT00904995 is a clinical study titled "Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis". Objectives: To investigate the relationship between the administration of intravenous (IV) and oral voriconazole (vori) and the occurrence of false positive (1,3) beta-d- glucan (BG) relative to the standard assessment criteria used to diagnose invasive fungal infection in patients with hematologic...
What is the current status of trial NCT00904995?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 23 participants. The study started on 2009-05. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00904995?
The interventions under investigation include: Voriconazole (DRUG).
Who is sponsoring clinical trial NCT00904995?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.